- Home
- / Lonza Biologics Porrino
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lonza Biologics Porrino financials data including stock price, CreditSafe score, income statement, and balance sheet.
Revenue
€120.1 M
FY, 2020
CreditSafe Score
?
Score changed on Jul 20, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|
| Revenue | 109.5M | 106.7M | 120.1M |
| Cost of goods sold | 59.4M | 56.1M | 70.6M |
| Gross profit | 50.1M | 50.7M | 49.5M |
| Gross profit margin, % | 45.7% | 47.5% | 41.2% |
| General and administrative expense | 21.8M | 24.3M | 26.7M |
| Operating expense total | 39.2M | 42.7M | 46.0M |
| Depreciation and amortization | 7.2M | 7.2M | 7.4M |
| EBIT | 11.2M | 9.3M | 7.8M |
| EBIT margin, % | 10.2% | 8.7% | 6.5% |
| Interest income | 8.0K | 6.0K | 838.0K |
| Interest expense | 16.0K | 22.0K | 154.0K |
| Pre tax profit | 11.1M | 9.3M | 8.4M |
| Income tax expense | 2.8M | 2.0M | (611.0K) |
| Net Income | 8.3M | 7.3M | 9.1M |